Latest updates for $Qnrx

Fresh curated links around $QNRX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • Recursion (RXRX) Q2 2026 Earnings Call Transcript
  • Recursion Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
  • Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

fool.com /4 weeks ago

Recursion (RXRX) Q2 2026 Earnings Call Transcript

AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.

Read source
seekingalpha.com /4 weeks ago

Recursion Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Read source
fool.com /3 weeks ago

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Revenue guidance slashed as commercial execution stumbles and academic spending weakens.

Read source
fool.com /4 weeks ago

Ultragenyx (RARE) Q2 2026 Earnings Call Transcript

Record revenue of $214 million signals momentum ahead of gene therapy launches.

Read source
fool.com /4 weeks ago

Pacira (PCRX) Q2 2026 Earnings Call Transcript

EXPAREL revenue grew 3% while company divested iovera and expanded insurance coverage.

Read source
seekingalpha.com /1 week ago

Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan

Read source
fool.com /1 month ago

Alnylam (ALNY) Q2 2026 Earnings Call Transcript

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Read source
fool.com /1 month ago

Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Read source
seekingalpha.com /1 month ago

RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript

Read source
seekingalpha.com /3 weeks ago

Quantum-Si incorporated (QSI) Q2 2026 Earnings Call Transcript

Read source
seekingalpha.com /3 weeks ago

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

Read source
seekingalpha.com /2 weeks ago

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

Read source
fool.com /4 weeks ago

Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript

Royalty receipts surged 14% as guidance raised for second consecutive quarter.

Read source
fool.com /1 month ago

Geron (GERN) Q2 2026 Earnings Call Transcript

RYTELO demand grew 5% as prescribing accounts hit 1,575 since launch.

Read source
seekingalpha.com /3 weeks ago

Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow

Read source
newswire.com /3 weeks ago

TRNR Reports Record Q2 2026 Results, Driven by 445% Revenue Growth; Confirms 2026 Pro Forma Revenue Guidance of More Tha...

Q2 2026 Reported Revenue of $6.6 Million, a 445% Increase Compared to Q2 2025Adjusted EBITDA (non-GAAP) Loss Reduced to $0.6 Million From $1.8 Million in Q1 2026Company Expects 202...

Read source
finance.yahoo.com /4 days ago

Acquisitive Strategy Offers Long-Term Prospects for QXO Inc. (QXO) Despite Dilution and Integration Risks

Read source
seekingalpha.com /1 month ago

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Read source
seekingalpha.com /1 month ago

Qiagen: New Launches Signal A Turnaround

Read source
finance.yahoo.com /1 month ago

Rigel Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Read source
qchron.com /1 month ago

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so farAnti...

Read source
investing.com /1 month ago

Form S-3 Quince Therapeutics For: 31 July

Read source
fool.com /3 weeks ago

Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript

Apitegromab awaits FDA decision on Sept. 30 for spinal muscular atrophy treatment.

Read source
seekingalpha.com /1 month ago

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Sources covering $Qnrx

seekingalpha.com

Recent coverage from public sources
Public source

finance.yahoo.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

fool.com

Recent coverage from public sources
Public source

investing.com

Recent coverage from public sources
Public source